Ok_老虎社区_美港股上老虎

Leekeez
2021-12-16

Samsara, Genenta Science Shares Went Public. Here’s How They Did.<blockquote>轮回，Genenta Science股票上市。他们是这样做的。</blockquote>

The market for initial public offerings is heading into the home stretch this week with Samsara, an

Samsara, Genenta Science Shares Went Public. Here’s How They Did.<blockquote>轮回，Genenta Science股票上市。他们是这样做的。</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":690072159,"tweetId":"690072159","gmtCreate":1639617761158,"gmtModify":1639617761548,"author":{"id":4089085863454690,"idStr":"4089085863454690","authorId":4089085863454690,"authorIdStr":"4089085863454690","name":"Leekeez","avatar":"https://static.tigerbbs.com/0dc7b69aff39f86a9dc2217fe596c9af","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":42,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690072159","repostId":1183248520,"repostType":4,"repost":{"id":"1183248520","kind":"news","pubTimestamp":1639617602,"share":"https://www.laohu8.com/m/news/1183248520?lang=zh_CN&edition=full","pubTime":"2021-12-16 09:20","market":"us","language":"en","title":"Samsara, Genenta Science Shares Went Public. Here’s How They Did.<blockquote>轮回，Genenta Science股票上市。他们是这样做的。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1183248520","media":"Barrons","summary":"The market for initial public offerings is heading into the home stretch this week with Samsara, an ","content":"The market for initial public offerings is heading into the home stretch this week with Samsara, an internet of things company, and biotech Genenta Science opening for trading Wednesday.<blockquote>随着物联网公司Samsara和生物技术公司Genenta Science周三开盘交易，首次公开募股市场本周进入冲刺阶段。</blockquote> Samsara stock rose by more than 7%, while Genenta slipped below its IPO price.<blockquote>Samsara股价上涨超过7%，而Genenta则跌破IPO价格。</blockquote> Roughly six companies were expected to list their shares this week. Sidus Space (ticker: SIDU), a satellite company, soared nearly 144% during its debut Wednesday, while Fresh Vine Wine (VINE), a producer of low-carb wine, dropped below its offer price. Two companies, biotechs&nbsp;Bionomics&nbsp;and Immix Biopharma, are slated to begin trading Thursday.<blockquote>预计本周将有大约六家公司上市。卫星公司Sidus Space（股票代码：SIDU）周三上市时股价飙升近144%，而低碳水化合物葡萄酒生产商Fresh Vine Wine(VINE)则跌破发行价。Biotechs Bionomics和Immix Biopharma两家公司定于周四开始交易。</blockquote> Samsara&nbsp;(ticker: IOT) is the most notable IPO this week. Shares of the Internet-of-things firm kicked off at $24.90 and closed at $24.70, up $1.70 from its offer price.<blockquote>Samsara（股票代码：IOT）是本周最引人注目的IPO。这家物联网公司的股价开盘价为24.90美元，收盘价为24.70美元，较发行价上涨1.70美元。</blockquote> The company raised $805 million after selling 35 million shares at $23 each, the top of its $20-to-$23 price range.<blockquote>该公司以每股23美元的价格出售3500万股股票后筹集了8.05亿美元，这是其20至23美元价格区间的上限。</blockquote> At $24.70 a share, Samsara’s valuation is $12.3 billion. Morgan Stanley, Goldman Sachs, J.P.Morgan, and Allen &amp; Co. are lead underwriters on the deal.<blockquote>按每股24.70美元计算，Samsara的估值为123亿美元。摩根士丹利、高盛、摩根大通和艾伦公司是此次交易的主承销商。</blockquote> Founded in 2015 by CEO Sanjit Biswas and John Bicket, chief technology officer, San Francisco-based Samsara provides a connected operations cloud and sensors that are used by companies to manage their vehicle fleets and industrial operations. (Biswas and Bicket previously founded cloud infrastructure start-up Meraki which they sold to&nbsp;Cisco&nbsp;Systems (CSCO) in 2012.)<blockquote>总部位于旧金山的Samsara由首席执行官Sanjit Biswas和首席技术官John Bicket于2015年创立，提供互联运营云和传感器，供公司用于管理其车队和工业运营。（Biswas和Bicket此前创立了云基础设施初创公司Meraki，并于2012年将其出售给思科系统(CSCO)。）</blockquote> Samsara’s technology collects data including video footage, people, and motion-detection, GPS location, and energy consumption. Companies can use this information to improve safety, lower insurance costs, and reduce the need for manual oversight and judgment, the prospectus said.<blockquote>Samsara的技术收集数据，包括视频片段、人员、运动检测、GPS定位和能源消耗。招股说明书称，公司可以利用这些信息来提高安全性、降低保险成本并减少人工监督和判断的需要。</blockquote> Samsara has raised $930 million in funding, according to Crunchbase. This includes a $400 million funding round in May 2020 from investors including asset manager AllianceBernstein, investment firm Franklin Templeton, private-equity firms General Atlantic and Warburg Pincus, along with hedge fund Sands Capital Management, a statement from that time said.<blockquote>据Crunchbase称，Samsara已筹集9.3亿美元资金。当时的一份声明称，这包括2020年5月的一轮4亿美元融资，投资者包括资产管理公司联博、投资公司富兰克林邓普顿、私募股权公司General Atlantic和Warburg Pincus以及对冲基金Sands Capital Management。</blockquote> Andreessen Horowitz, a venture firm that often invests in technology startups, will have 17.5% of Samsara total voting power, while General Catalyst, a venture-capital firm, will hold nearly 10%.<blockquote>经常投资科技初创公司的风险投资公司Andreessen Horowitz将拥有Samsara总投票权的17.5%，而风险投资公司General Catalyst将持有近10%。</blockquote> Shares of&nbsp;Genenta Science&nbsp;(GNTA) opened at $10.05 and ended at $11, down more than 4% from its offer price.<blockquote>Genenta Science(GNTA)的股价开盘价为10.05美元，收于11美元，较发行价下跌超过4%。</blockquote> Genenta Science’s much smaller IPO collected about $36 million. The Milan, Italy-based biotech sold 2.4 million American depositary shares, or ADSs, at $11.50 each, the middle of its $10.50-to-$12.50 price range. Each ADS represents one ordinary share. Roth Capital Partners is underwriter on the deal.<blockquote>Genenta Science的IPO规模要小得多，筹集了约3600万美元。这家总部位于意大利米兰的生物技术公司以每股11.50美元的价格出售了240万股美国存托股票(ADS)，处于10.50美元至12.50美元价格范围的中间位置。每份美国存讬股份代表一股普通股。Roth Capital Partners是该交易的承销商。</blockquote> Genenta is developing hematopoietic stem-cell gene therapies. Its lead product candidate, Temferon, treats glioblastoma multiforme, or GBM, a common malignant primary brain tumor. The company said it is currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed GBM patients in Italy.<blockquote>Genenta正在开发造血干细胞基因疗法。其主要候选产品Temferon治疗多形性胶质母细胞瘤（GBM），一种常见的恶性原发性脑肿瘤。该公司表示，目前正在意大利新诊断的GBM患者中进行Temferon的1/2期剂量递增临床试验。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsara, Genenta Science Shares Went Public. Here’s How They Did.<blockquote>轮回，Genenta Science股票上市。他们是这样做的。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsara, Genenta Science Shares Went Public. Here’s How They Did.<blockquote>轮回，Genenta Science股票上市。他们是这样做的。</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-12-16 09:20\n\n</h4>\n</header>\n<article>\nThe market for initial public offerings is heading into the home stretch this week with Samsara, an internet of things company, and biotech Genenta Science opening for trading Wednesday.<blockquote>随着物联网公司Samsara和生物技术公司Genenta Science周三开盘交易，首次公开募股市场本周进入冲刺阶段。</blockquote> Samsara stock rose by more than 7%, while Genenta slipped below its IPO price.<blockquote>Samsara股价上涨超过7%，而Genenta则跌破IPO价格。</blockquote> Roughly six companies were expected to list their shares this week. Sidus Space (ticker: SIDU), a satellite company, soared nearly 144% during its debut Wednesday, while Fresh Vine Wine (VINE), a producer of low-carb wine, dropped below its offer price. Two companies, biotechs&nbsp;Bionomics&nbsp;and Immix Biopharma, are slated to begin trading Thursday.<blockquote>预计本周将有大约六家公司上市。卫星公司Sidus Space（股票代码：SIDU）周三上市时股价飙升近144%，而低碳水化合物葡萄酒生产商Fresh Vine Wine(VINE)则跌破发行价。Biotechs Bionomics和Immix Biopharma两家公司定于周四开始交易。</blockquote> Samsara&nbsp;(ticker: IOT) is the most notable IPO this week. Shares of the Internet-of-things firm kicked off at $24.90 and closed at $24.70, up $1.70 from its offer price.<blockquote>Samsara（股票代码：IOT）是本周最引人注目的IPO。这家物联网公司的股价开盘价为24.90美元，收盘价为24.70美元，较发行价上涨1.70美元。</blockquote> The company raised $805 million after selling 35 million shares at $23 each, the top of its $20-to-$23 price range.<blockquote>该公司以每股23美元的价格出售3500万股股票后筹集了8.05亿美元，这是其20至23美元价格区间的上限。</blockquote> At $24.70 a share, Samsara’s valuation is $12.3 billion. Morgan Stanley, Goldman Sachs, J.P.Morgan, and Allen &amp; Co. are lead underwriters on the deal.<blockquote>按每股24.70美元计算，Samsara的估值为123亿美元。摩根士丹利、高盛、摩根大通和艾伦公司是此次交易的主承销商。</blockquote> Founded in 2015 by CEO Sanjit Biswas and John Bicket, chief technology officer, San Francisco-based Samsara provides a connected operations cloud and sensors that are used by companies to manage their vehicle fleets and industrial operations. (Biswas and Bicket previously founded cloud infrastructure start-up Meraki which they sold to&nbsp;Cisco&nbsp;Systems (CSCO) in 2012.)<blockquote>总部位于旧金山的Samsara由首席执行官Sanjit Biswas和首席技术官John Bicket于2015年创立，提供互联运营云和传感器，供公司用于管理其车队和工业运营。（Biswas和Bicket此前创立了云基础设施初创公司Meraki，并于2012年将其出售给思科系统(CSCO)。）</blockquote> Samsara’s technology collects data including video footage, people, and motion-detection, GPS location, and energy consumption. Companies can use this information to improve safety, lower insurance costs, and reduce the need for manual oversight and judgment, the prospectus said.<blockquote>Samsara的技术收集数据，包括视频片段、人员、运动检测、GPS定位和能源消耗。招股说明书称，公司可以利用这些信息来提高安全性、降低保险成本并减少人工监督和判断的需要。</blockquote> Samsara has raised $930 million in funding, according to Crunchbase. This includes a $400 million funding round in May 2020 from investors including asset manager AllianceBernstein, investment firm Franklin Templeton, private-equity firms General Atlantic and Warburg Pincus, along with hedge fund Sands Capital Management, a statement from that time said.<blockquote>据Crunchbase称，Samsara已筹集9.3亿美元资金。当时的一份声明称，这包括2020年5月的一轮4亿美元融资，投资者包括资产管理公司联博、投资公司富兰克林邓普顿、私募股权公司General Atlantic和Warburg Pincus以及对冲基金Sands Capital Management。</blockquote> Andreessen Horowitz, a venture firm that often invests in technology startups, will have 17.5% of Samsara total voting power, while General Catalyst, a venture-capital firm, will hold nearly 10%.<blockquote>经常投资科技初创公司的风险投资公司Andreessen Horowitz将拥有Samsara总投票权的17.5%，而风险投资公司General Catalyst将持有近10%。</blockquote> Shares of&nbsp;Genenta Science&nbsp;(GNTA) opened at $10.05 and ended at $11, down more than 4% from its offer price.<blockquote>Genenta Science(GNTA)的股价开盘价为10.05美元，收于11美元，较发行价下跌超过4%。</blockquote> Genenta Science’s much smaller IPO collected about $36 million. The Milan, Italy-based biotech sold 2.4 million American depositary shares, or ADSs, at $11.50 each, the middle of its $10.50-to-$12.50 price range. Each ADS represents one ordinary share. Roth Capital Partners is underwriter on the deal.<blockquote>Genenta Science的IPO规模要小得多，筹集了约3600万美元。这家总部位于意大利米兰的生物技术公司以每股11.50美元的价格出售了240万股美国存托股票(ADS)，处于10.50美元至12.50美元价格范围的中间位置。每份美国存讬股份代表一股普通股。Roth Capital Partners是该交易的承销商。</blockquote> Genenta is developing hematopoietic stem-cell gene therapies. Its lead product candidate, Temferon, treats glioblastoma multiforme, or GBM, a common malignant primary brain tumor. The company said it is currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed GBM patients in Italy.<blockquote>Genenta正在开发造血干细胞基因疗法。其主要候选产品Temferon治疗多形性胶质母细胞瘤（GBM），一种常见的恶性原发性脑肿瘤。该公司表示，目前正在意大利新诊断的GBM患者中进行Temferon的1/2期剂量递增临床试验。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/samsara-genenta-ipos-stock-51639586497?mod=hp_LATEST\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOT":"Samsara, Inc.","GNTA":"Genenta Science S.p.A."},"source_url":"https://www.barrons.com/articles/samsara-genenta-ipos-stock-51639586497?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183248520","content_text":"The market for initial public offerings is heading into the home stretch this week with Samsara, an internet of things company, and biotech Genenta Science opening for trading Wednesday.\nSamsara stock rose by more than 7%, while Genenta slipped below its IPO price.\nRoughly six companies were expected to list their shares this week. Sidus Space (ticker: SIDU), a satellite company, soared nearly 144% during its debut Wednesday, while Fresh Vine Wine (VINE), a producer of low-carb wine, dropped below its offer price. Two companies, biotechs Bionomics and Immix Biopharma, are slated to begin trading Thursday.\nSamsara (ticker: IOT) is the most notable IPO this week. Shares of the Internet-of-things firm kicked off at $24.90 and closed at $24.70, up $1.70 from its offer price.\nThe company raised $805 million after selling 35 million shares at $23 each, the top of its $20-to-$23 price range.\nAt $24.70 a share, Samsara’s valuation is $12.3 billion. Morgan Stanley, Goldman Sachs, J.P.Morgan, and Allen & Co. are lead underwriters on the deal.\nFounded in 2015 by CEO Sanjit Biswas and John Bicket, chief technology officer, San Francisco-based Samsara provides a connected operations cloud and sensors that are used by companies to manage their vehicle fleets and industrial operations. (Biswas and Bicket previously founded cloud infrastructure start-up Meraki which they sold to Cisco Systems (CSCO) in 2012.)\nSamsara’s technology collects data including video footage, people, and motion-detection, GPS location, and energy consumption. Companies can use this information to improve safety, lower insurance costs, and reduce the need for manual oversight and judgment, the prospectus said.\nSamsara has raised $930 million in funding, according to Crunchbase. This includes a $400 million funding round in May 2020 from investors including asset manager AllianceBernstein, investment firm Franklin Templeton, private-equity firms General Atlantic and Warburg Pincus, along with hedge fund Sands Capital Management, a statement from that time said.\nAndreessen Horowitz, a venture firm that often invests in technology startups, will have 17.5% of Samsara total voting power, while General Catalyst, a venture-capital firm, will hold nearly 10%.\nShares of Genenta Science (GNTA) opened at $10.05 and ended at $11, down more than 4% from its offer price.\nGenenta Science’s much smaller IPO collected about $36 million. The Milan, Italy-based biotech sold 2.4 million American depositary shares, or ADSs, at $11.50 each, the middle of its $10.50-to-$12.50 price range. Each ADS represents one ordinary share. Roth Capital Partners is underwriter on the deal.\nGenenta is developing hematopoietic stem-cell gene therapies. Its lead product candidate, Temferon, treats glioblastoma multiforme, or GBM, a common malignant primary brain tumor. The company said it is currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed GBM patients in Italy.","news_type":1,"symbols_score_info":{"GNTA":0.9,"IOT":0.9}},"isVote":1,"tweetType":1,"viewCount":3485,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}